CRISPR Therapeutics’ (CRSP) “Sector Perform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their sector perform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has a $53.00 price objective on the stock.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Tuesday, October 29th. Truist Financial cut their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Chardan Capital lowered their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Barclays cut their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Trading Up 0.8 %

Shares of CRISPR Therapeutics stock opened at $51.15 on Wednesday. CRISPR Therapeutics has a twelve month low of $43.42 and a twelve month high of $91.10. The firm’s 50-day moving average price is $47.29 and its 200 day moving average price is $52.24. The firm has a market capitalization of $4.35 billion, a PE ratio of -15.70 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter last year, the business earned ($1.41) EPS. On average, sell-side analysts predict that CRISPR Therapeutics will post -5.57 EPS for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the transaction, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Cetera Investment Advisers lifted its stake in CRISPR Therapeutics by 451.3% during the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock worth $2,324,000 after purchasing an additional 27,915 shares during the last quarter. CWM LLC lifted its position in shares of CRISPR Therapeutics by 11,871.1% during the 2nd quarter. CWM LLC now owns 22,386 shares of the company’s stock worth $1,209,000 after buying an additional 22,199 shares during the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after buying an additional 22,583 shares in the last quarter. Granite Bay Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at $2,375,000. Finally, Krilogy Financial LLC raised its stake in CRISPR Therapeutics by 92.9% during the 2nd quarter. Krilogy Financial LLC now owns 20,872 shares of the company’s stock worth $1,127,000 after acquiring an additional 10,050 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.